Funding for IanTECH’s Next Generation Ophthalmic Device Supports Goal to Alleviate Cataract-induced Blindness in 25 Million.
Visionary Ventures
Life sciences venture capital fund investing in ophthalmology and medical aesthetics.
Funding for IanTECH’s Next Generation Ophthalmic Device Supports Goal to Alleviate Cataract-induced Blindness in 25 Million.